These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 26429955

  • 1. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
    Persson M, Nedergaard MK, Brandt-Larsen M, Skovgaard D, Jørgensen JT, Michaelsen SR, Madsen J, Lassen U, Poulsen HS, Kjaer A.
    J Nucl Med; 2016 Feb; 57(2):272-8. PubMed ID: 26429955
    [Abstract] [Full Text] [Related]

  • 2. Improved positron emission tomography imaging of glioblastoma cancer using novel 68Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR).
    Loft MD, Sun Y, Liu C, Christensen C, Huang D, Kjaer A, Cheng Z.
    Amino Acids; 2017 Jun; 49(6):1089-1100. PubMed ID: 28316028
    [Abstract] [Full Text] [Related]

  • 3. First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.
    Persson M, Liu H, Madsen J, Cheng Z, Kjaer A.
    Nucl Med Biol; 2013 Jul; 40(5):618-24. PubMed ID: 23602763
    [Abstract] [Full Text] [Related]

  • 4. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion.
    Persson M, Madsen J, Østergaard S, Jensen MM, Jørgensen JT, Juhl K, Lehmann C, Ploug M, Kjaer A.
    J Nucl Med; 2012 Jan; 53(1):138-45. PubMed ID: 22213823
    [Abstract] [Full Text] [Related]

  • 5. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
    Persson M, Madsen J, Østergaard S, Ploug M, Kjaer A.
    Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
    [Abstract] [Full Text] [Related]

  • 6. Safety, Dosimetry, and Tumor Detection Ability of 68Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging.
    Skovgaard D, Persson M, Brandt-Larsen M, Christensen C, Madsen J, Klausen TL, Holm S, Andersen FL, Loft A, Berthelsen AK, Pappot H, Brasso K, Kroman N, Højgaard L, Kjaer A.
    J Nucl Med; 2017 Mar; 58(3):379-386. PubMed ID: 27609788
    [Abstract] [Full Text] [Related]

  • 7. Urokinase-Type Plasminogen Activator Receptor (uPAR) Expression and [64Cu]Cu-DOTA-AE105 uPAR-PET/CT in Patient-Derived Xenograft Models of Oral Squamous Cell Carcinoma.
    Lawaetz M, Binderup T, Christensen A, Juhl K, Lelkaitis G, Lykke E, Knudsen L, von Buchwald C, Kjaer A.
    Mol Imaging Biol; 2023 Dec; 25(6):1034-1044. PubMed ID: 37749438
    [Abstract] [Full Text] [Related]

  • 8. Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with 18F-FDG PET/CT: A Single-Center Prospective Study.
    Risør LM, Clausen MM, Ujmajuridze Z, Farhadi M, Andersen KF, Loft A, Friborg J, Kjaer A.
    J Nucl Med; 2022 Aug; 63(8):1169-1176. PubMed ID: 34857658
    [Abstract] [Full Text] [Related]

  • 9. Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging.
    Persson M, El Ali HH, Binderup T, Pfeifer A, Madsen J, Rasmussen P, Kjaer A.
    Nucl Med Biol; 2014 Mar; 41(3):290-5. PubMed ID: 24533988
    [Abstract] [Full Text] [Related]

  • 10. Prospective Phase II Trial of Prognostication by 68Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy.
    Carlsen EA, Loft M, Loft A, Berthelsen AK, Langer SW, Knigge U, Kjaer A.
    J Nucl Med; 2022 Sep; 63(9):1371-1377. PubMed ID: 35058319
    [Abstract] [Full Text] [Related]

  • 11. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
    Persson M, Rasmussen P, Madsen J, Ploug M, Kjaer A.
    Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
    [Abstract] [Full Text] [Related]

  • 12. In vivo detection of urokinase-type plasminogen activator receptor (uPAR) expression in arterial atherogenesis using [64Cu]Cu-DOTA-AE105 positron emission tomography (PET).
    Khare HA, Døssing KBV, Ringgaard L, Christensen E, Urbak L, Sillesen H, Ripa RS, Binderup T, Pedersen SF, Kjaer A.
    Atherosclerosis; 2022 Jul; 352():103-111. PubMed ID: 35396143
    [Abstract] [Full Text] [Related]

  • 13. Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies.
    Persson M, Hosseini M, Madsen J, Jørgensen TJ, Jensen KJ, Kjaer A, Ploug M.
    Theranostics; 2013 Jul; 3(9):618-32. PubMed ID: 24052804
    [Abstract] [Full Text] [Related]

  • 14. Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET.
    Li ZB, Niu G, Wang H, He L, Yang L, Ploug M, Chen X.
    Clin Cancer Res; 2008 Aug 01; 14(15):4758-66. PubMed ID: 18676745
    [Abstract] [Full Text] [Related]

  • 15. Urokinase Plasminogen Activator Receptor-PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand.
    Skovgaard D, Persson M, Kjaer A.
    PET Clin; 2017 Jul 01; 12(3):311-319. PubMed ID: 28576169
    [Abstract] [Full Text] [Related]

  • 16. A novel urokinase plasminogen activator receptor-targeted peptide-based probe for in-vivo molecular imaging of glioblastoma.
    Han Y, Tu L, Zhang Y, Xu L, Sun Z.
    Nucl Med Commun; 2023 Feb 01; 44(2):142-149. PubMed ID: 36630218
    [Abstract] [Full Text] [Related]

  • 17. Noninvasive Detection of HER2 Expression in Gastric Cancer by 64Cu-NOTA-Trastuzumab in PDX Mouse Model and in Patients.
    Guo X, Zhu H, Zhou N, Chen Z, Liu T, Liu F, Xu X, Jin H, Shen L, Gao J, Yang Z.
    Mol Pharm; 2018 Nov 05; 15(11):5174-5182. PubMed ID: 30251865
    [Abstract] [Full Text] [Related]

  • 18. PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule.
    Su X, Cheng K, Liu Y, Hu X, Meng S, Cheng Z.
    Amino Acids; 2015 Jul 05; 47(7):1409-19. PubMed ID: 25854877
    [Abstract] [Full Text] [Related]

  • 19. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS.
    J Nucl Med; 2004 Oct 05; 45(10):1776-83. PubMed ID: 15471848
    [Abstract] [Full Text] [Related]

  • 20. uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
    Persson M, Juhl K, Rasmussen P, Brandt-Larsen M, Madsen J, Ploug M, Kjaer A.
    Mol Pharm; 2014 Aug 04; 11(8):2796-806. PubMed ID: 24955765
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.